I don't know why you longs are so happy about the Lincoln Park deal. The shares you won have just been diluted. LOL
Where are you getting your information? As far as I can tell, tivantinib is not being studied for Her2 positive breast cancer. If you are going to pump the stock, at least do it correctly.
WOW, you are incredibly naïve. Do you really think a company can be scammed into spending 7 billion?
WOW. You are saying the 16.6 months "is not even close" to 16.7 months? I give up. You can continue to believe whatever you like.
Your quote is exact. What is says it that the neratinib combo is equivalent to the Herceptin combo. That is, there is no statistically significant difference between the two treatments. The herceptin combo is the standard of care. Therefore the neratinib combo is as good as the standard of care. That is hardly a failure. In addition, if you read further down in the press release, you will note that with respect to brain metastasis the neratinib combo is statistically significantly better than the Herceptin combo. Thus, in this respect, the neratinib combo is superior to the standard of care. I can't explain it more simply for you. Do you now understand?
Did you actually read the press release or listen to the presentation? Both the primary and secondary were met. Tell us what the primary was and tell us how it was not met. Show us the facts.
My god, it is incredible how you short sellers can lie. The primary endpoint was progression free survival (PFS) and was completely met. The study basically showed neratinib/paclitaxel is equivalent to trastuzumab/paclitaxel. The PFS and ORR for the neratinib/paclitaxel arm were 16.6 months and 74.8%, respectively versus 16.7 months and 75.1%, respectively, for the trastuzumab/paclitaxel arm. The differences were not statistically significant. This result was totally expected. In addition, it was the found the the neratinib combo was far superior to the Herceptin combo in treating brain metastasis. For those who have the time and inclination read the actual press release and not listen to ignorant posters on this board.
It didn't fail. Very sloppy reporting. Apparently the reporters don't understand the data. Read the actual press release or listen to the presentation on the Puma web site.
However, the neratinib combo was far better than the herceptin combo in targeting brain mets. I recommend those interested to read the full press release.
The Reuters article posted on Yahoo is completely wrong. It must have been written by morons. Search for "Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)" and read the full press release. The results of the trial are quite positive.
Actually the results are good. The study showed the neratinib was as good as Herceptin. Since these drugs target different portions of the her2 receptor, they could be used together. That could be a major break though in treating breast cancer. I see this price drop as good buying opportunity.
yes indeed, another clinical trial will be needed for concurrent use of neratinib and perjeta, but that trial could be run after neratinib approval.
Sorry, but only an idiot would believe that PUMA could "scam a co into paying them billions of dollars". I just can't understand how there are people like you who are so naive. Is it a genetic or acquired characteristic?
So, let me get this straight. In your version there is a conspiracy between Puma and the FDA. Puma has the FDA in "their pocket". Well, if this is the case, then the FDA will surely approve the drug.
So, tell us why all the insiders sold all their stock. What do they know that we don't? Why did they hire a firm to pump up the stock price before doing so? No matter what these early results show, that sale of stock by the insiders will keep the stock price down. Its not the Street bashers but the management that has depressed and will continue to depress the price.